Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 9/2019

01-09-2019 | Human Immunodeficiency Virus | Original Paper

Incentives for Viral Suppression in People Living with HIV: A Randomized Clinical Trial

Authors: Kenneth Silverman, August F. Holtyn, Andrew M. Rodewald, Robert F. Siliciano, Brantley P. Jarvis, Shrinidhi Subramaniam, Jeannie-Marie Leoutsakos, Carol-Ann Getty, Sebastian Ruhs, Mark A. Marzinke, Michael Fingerhood

Published in: AIDS and Behavior | Issue 9/2019

Login to get access

Abstract

The HIV/AIDS epidemic can be eliminated if 73% of people living with HIV take antiretroviral medications and achieve undetectable viral loads. This study assessed the effects of financial incentives in suppressing viral load. People living with HIV with detectable viral loads (N = 102) were randomly assigned to Usual Care or Incentive groups. Incentive participants earned up to $10 per day for 2 years for providing blood samples that showed either reduced or undetectable viral loads. This report presents data on the 1st year after random assignment. Incentive participants provided more (adjusted OR = 15.6, CI 4.2–58.8, p < 0.001) blood samples at 3-month assessments with undetectable viral load (72.1%) than usual care control participants (39.0%). We collected most blood samples. The study showed that incentives can substantially increase undetectable viral loads in people living with HIV. Financial incentives for suppressed viral loads could contribute to the eradication of the HIV/AIDS epidemic.
Literature
1.
Montaner JS, Wood E, Kerr T, et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):5.CrossRef
2.
Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451–2.CrossRef
3.
Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future. AIDS Res Ther. 2016;13:35 eCollection.CrossRef
4.
5.
6.
Mathes T, Pieper D, Antoine SL, Eikermann M. Adherence-enhancing interventions for highly active antiretroviral therapy in HIV-infected patients—a systematic review. HIV Med. 2013;14(10):583–95.CrossRef
7.
Mbuagbaw L, Sivaramalingam B, Navarro T, et al. Interventions for enhancing adherence to antiretroviral therapy (ART): a systematic review of high quality studies. AIDS Patient Care STDS. 2015;29(5):248–66.CrossRef
8.
Kanters S, Park JJ, Chan K, et al. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. Lancet HIV. 2017;4(1):e40.CrossRef
9.
Pilling S, Strang J, Gerada C. NICE. Psychosocial interventions and opioid detoxification for drug misuse: summary of NICE guidance. BMJ. 2007;335(7612):203–5.CrossRef
10.
Halpern SD, Harhay MO, Saulsgiver K, Brophy C, Troxel AB, Volpp KG. A pragmatic trial of e-cigarettes, incentives, and drugs for smoking cessation. N Engl J Med. 2018;378(24):2302–10.CrossRef
11.
Halpern SD, French B, Small DS, et al. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med. 2015;372(22):2108–17.CrossRef
12.
Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006;101(2):192–203.CrossRef
13.
Bickel WK, Johnson MW, Koffarnus MN, Mackillop J, Murphy JG. The behavioral economics of substance use disorders: reinforcement pathologies and their repair. Annu Rev Clin Psychol. 2014;10:641–77.CrossRef
14.
El-Sadr WM, Donnell D, Beauchamp G, et al. Financial incentives for linkage to care and viral suppression among HIV-positive patients: a randomized clinical trial (HPTN 065). JAMA Intern Med. 2017;177(8):1083–92.CrossRef
15.
Metsch LR, Feaster DJ, Gooden L, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156–70.CrossRef
16.
Silverman K, Chutuape MA, Bigelow GE, Stitzer ML. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacology. 1999;146(2):128–38.CrossRef
17.
Silverman K, Kaminski BJ, Higgins ST, Brady JV. Behavior analysis and treatment of drug addiction. In: Fisher WW, Piazza CC, Roane HS, editors. Handbook of applied behavior analysis. New York: Guilford Press; 2011. p. 451–71.
18.
19.
Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000;15(12):841–7.CrossRef
20.
Rosen MI, Dieckhaus K, McMahon TJ, et al. Improved adherence with contingency management. AIDS Patient Care STDS. 2007;21(1):30–40.CrossRef
21.
Sorensen JL, Haug NA, Delucchi KL, et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007;88(1):54–63.CrossRef
22.
Silverman K, Wong CJ, Higgins ST, et al. Increasing opiate abstinence through voucher-based reinforcement therapy. Drug Alcohol Depend. 1996;41(2):157–65.CrossRef
23.
Silverman K, Higgins ST, Brooner RK, et al. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry. 1996;53(5):409–15.CrossRef
24.
Silverman K, Wong CJ, Umbricht-Schneiter A, Montoya ID, Schuster CR, Preston KL. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol. 1998;66(5):811–24.CrossRef
25.
Silverman K, Robles E, Mudric T, Bigelow GE, Stitzer ML. A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs. J Consult Clin Psychol. 2004;72(5):839–54.CrossRef
26.
Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54(2):127–35.CrossRef
27.
28.
Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther. 1997;35(8):785–91.CrossRef
29.
Parker RM, Baker DW, Williams MV, Nurss JR. The test of functional health literacy in adults: a new instrument for measuring patients’ literacy skills. J Gen Intern Med. 1995;10(10):537–41.CrossRef
30.
Johnson MW, Bickel WK. The behavioral economics of cigarette smoking: the concurrent presence of a substitute and an independent reinforcer. Behav Pharmacol. 2003;14(2):137–44.CrossRef
31.
Wilkinson GS. WRAT-3: Wide range achievement test administration manual. Wilmington, DE: Wide Range, Inc.; 1993.
32.
McLellan AT, Luborsky L, Cacciola J, et al. New data from the addiction severity index: reliability and validity in three centers. J Nerv Ment Dis. 1985;173(7):412–23.CrossRef
33.
Marzinke MA, Breaud A, Parsons TL, et al. The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta. 2014;433:157–68.CrossRef
34.
Buscher A, Hartman C, Kallen MA, Giordano TP. Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAART-naive HIV patients. HIV Clin Trials. 2011;12(5):244–54.CrossRef
35.
Purcell DW, Latka MH, Metsch LR, et al. Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr. 2007;46(Suppl 2):35.CrossRef
36.
Bray JW, Zarkin GA, Miller WR, et al. Measuring economic outcomes of alcohol treatment using the Economic Form 90. J Stud Alcohol Drugs. 2007;68(2):248–55.CrossRef
37.
Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049–60.CrossRef
38.
Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21(19):2917–30.CrossRef
39.
Liu G, Liang KY. Sample size calculations for studies with correlated observations. Biometrics. 1997;53(3):937–47.CrossRef
40.
Oldenburg CE, Perez-Brumer AG, Reisner SL. Poverty matters: contextualizing the syndemic condition of psychological factors and newly diagnosed HIV infection in the United States. AIDS. 2014;28(18):2763–9.CrossRef
41.
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844–5.CrossRef
Metadata
Title
Incentives for Viral Suppression in People Living with HIV: A Randomized Clinical Trial
Authors
Kenneth Silverman
August F. Holtyn
Andrew M. Rodewald
Robert F. Siliciano
Brantley P. Jarvis
Shrinidhi Subramaniam
Jeannie-Marie Leoutsakos
Carol-Ann Getty
Sebastian Ruhs
Mark A. Marzinke
Michael Fingerhood
Publication date
01-09-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 9/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02592-8

Other articles of this Issue 9/2019

AIDS and Behavior 9/2019 Go to the issue

Original Paper

A Cost and Cost–Threshold Analysis of Implementation of an Evidence-Based Intervention for HIV-Serodiscordant Couples

Original Paper

Effect of a Community-Level HIV Prevention Intervention on Psychosocial Determinants of HIV Risk Behaviors among Young Black Men Who Have Sex with Men (YBMSM)

Original Paper

Self-Reported Long-Term Antiretroviral Adherence: A Longitudinal Study Among HIV Infected Pregnant Women in Mpumalanga, South Africa

Substantive Review

Microfinance Interventions and HIV Treatment Outcomes: A Synthesizing Conceptual Framework and Systematic Review

Original Paper

HIV Care Trajectories as a Novel Longitudinal Assessment of Retention in Care

Original Paper

Attitudes Toward Long-Term Use of Antiretroviral Therapy Among HIV-Infected Pregnant Women in Moshi, Tanzania: A Longitudinal Study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits